Blakestone wrote: Isodiol has a lot going on right now, it's almost overwhelming for a new investor. Isodiol is currently involved with the following countries: U.S.A., Canada, Mexico, Brasil, China and U.K. The Company will further expand its plans for Jamaica and Columbia in the coming weeks.
Their net operational profit is positive, they have 26.4 million $ in the bank and gross profit margin of 54.4%. Current monthly revenue is at 3,316,646$ (month of May). Next financial statements: 31 july 2018 and 31 august 2018.
Financial information:
https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00036046
Isodiol is set for over 150 000 000$ revenue in fiscal 2019 from CBD isolate. A kg of CBD isolate sells for around 10 000$ and could easily reach 20 000$ when the demand grows.
"With the Medicines and Healthcare products regulatory approval and because it meets all legal requirements under international law, the Company is now able to export the pure, natural CBD anywhere in the world, subject to pharmaceutical regulations. This approval sets Isodiol apart from all other CBD companies globally as a secure and reliable supplier positioned to be able to serve this newly created demand for CBD drug development, approved pharmaceutical applications, research, clinical studies, and clinical trials. Upon completion of the company’s new state-of-the-art manufacturing facility in Q1-2019, the Company’s production output capabilities will increase to approximately 20,000 kilos of CBD – Active Pharmaceutical Ingredient quality input material annually."
What advantage does Isodiol have against its competitors? Read this with the knowledge that Isodiol has its CBD certified as an Active Pharmaceutical Ingredient (API):
The "Bioactivity" of the Cannabidiol (CBD) molecule, or any drug, is a complex interplay between its binding efficiency to a receptor, and its ability to produce a biological response— of quantitative magnitude. The announced CBD Bioactivity Test precisely measures the ability of a CBD sample to bind and produce an immunological response via the CB2 receptor.
"CBD is a source of many medical claims and the market has seen an explosion of CBD products. Consumers are paying premium prices for these products. They are completely ignorant of the fact that CBD is a biological molecule with 400% variation between batches. And worse, most of the products we have analyzed have very poor bioactivity. Making any medical claims on this is highly tenuous," says Donish Cushing, one of the authors of a scientific paper published today.
"All research papers published about CBD, from plant sources, have not accounted for variations in their bioactivity. I believe this has confounded research and produced inconsistent results so far. The inflorescence of the plant produces the best bioactivity. The stalks and stems the worst. Current regulations dictate that only stalks/stems can be used to manufacture CBD. Thus assuring the worst quality product. This inconsistency needs to be resolved by lawmakers," said Dr. Sharma Kristipati, Director of the newly set up lab to measure CBD Bioactivity.
"Governments are considering certifying CBD as an Active Pharmaceutical Ingredient (API). The products we have measured vary from 11% to 41% in Bioactivity. Too poor and too much variation. Governments should only certify CBD, as an API, if it has a Bioactivity greater than 80%," further added Dr. Sharma Kristipati.
Source: https://www.prnewswire.com/news-releases/peak-health-announces-filing-of-patent-applications-for-testing-the-bioactivity-of-the-cannabidiol-cbd-molecule-and-publication-of-scientific-paper-documenting-results-of-commercial-samples-300647519.html
Here is what Isodiol has accomplished and how it will increase its earnings that, I must say, are already very optimistic:
On April 26th, Isodiol's wholly owned subsidiary BSPG Laboratories, LTD. has received government approval from United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA), in accordance with The Human Medicines Regulations 2012 (SI 2012/1916), for the manufacturing of the active substance Cannabidiol (CBD) under certificate number: UK API 48727. Isodiol has commenced development on a new state-of-the-art processing facility in Yunnan, China that will have the ability to process over 15 metric-tons of hemp biomass daily for the extraction of cannabinoids and terpenes for use in medical, nutraceutical, food and cosmetic industries utilizing these technologies. The company believes this to be the highest capacity processing facility for CBD isolate in the world and is expected to be completed by Q1 2019.
On 5th february 2018, Isodiol has received approval from the Brazilian Health Regulatory Agency (ANVISA) for Isodiolex for the treatment of epilepsy and parkinson's disease. This product will be placed on the Special Category List for alternative therapies which will enable it to be prescribed by doctors and neurologists. This is now the Company’s second product to receive medical approval by the ANVISA. The first being Isoderm which received approval on July 6th 2017.
Isodiol is on a major revenue growth as they expand their presence internationally with the help of their 10 years licensing agreement with Kathy Ireland and Level Brands.
Isodiol has completed strategic financing with the well respected Serruya Private Equity inc. The Serruya Private Equity Inc. is a global private equity firm focused on transforming companies by collaborating with management to develop and implement strategies which leverage special-purpose entity’s existing operational and financial resources.
Isodiol announced that it has reached a partnership agreement with Cage Warriors, Europe’s leading Mixed Martial Arts (MMA) promotion through its brand ISO-Sport on February 12 2018. Cage Warriors prides itself on being the proving ground for MMA’s stars of the future and has been home to some of biggest stars of MMA’s past and present, including Conor McGregor, Michael Bisping, and Dan Hardy.
Isodiol intends to import CBD isolate to the following companies:
Up to 30kg per month to Nuuvera Holdings Limited.
Up to 5kg per month to Agrima Botanicals Corp.
A minimum of 3kg per month to Zenabis Ltd.
An undisclosed amount to Sundial Growers Inc.
Isodiol has acquired the following:
---On April 17 2018:
-BSPG Laboratories Limited (BSPGL-UK):organized in the United Kingdom, BSPGL-UK’s business includes, but is not limited to, an operating facility that refines the CBD molecule to a purity of >99.5%, is THC-Free and highly bioactive. Isodiol has acquired 100% of BSPGL-UK.
-Purodiol Do Brasil Ltda (PUR-Brazil):organized in Brazil, PUR-Brazil supplies Purodiol pharmaceutical products under ANVISA regulations to patients in Brazil and is currently involved in multiple clinical studies and trials. Isodiol has acquired 99% of PUR-Brazil, which provides an immediate boost to its revenue and substantially expands its customer base in South America.
-Three Pivotal Processing Patents from Hankang (Yunnan) Biotech Co., Ltd. (HBTC-China): Organized in China, HBTC-China extracts CBD that is used for R&D and commercial purposes. HBTC-China has successfully developed and patented a sophisticated industrial production process to extract CBD from hemp. The Company has purchased these three patents for processing and extracting CBD from HBTC-China and has also secured an exclusive off-take agreement for 100% of their CBD production, currently operating at 1.5 metric-tons daily.
--- KURE™ Corp. for 100% ownership on May 1st 2018. A leading specialty vape retailer headquartered in Charlotte, North Carolina, with retail locations throughout the United States. The KURE Vaporium & Lounge™ is a modern and sophisticated retail environment and lounge catering to the vaping community. By elevating the environment and customer experience, KURE has paved a completely new path to the rapidly growing vaping and e-cigarette industry and operates e-juice bars and lounges with plans for rapid domestic and international expansion. Both Isodiol International Inc. and KURE are clients of Level Brands, Inc. (NYSE American: LEVB), an innovative marketing and licensing company that provides bold, unconventional, and socially responsible branding for leading businesses. https://www.kurevapes.com
--- Farmtiva LLC (“Farmtiva”) for 51% ownership on June 4th 2018. A cultivator of hemp with operations in California that provides hemp farming and distribution support for farmers and other industry participants. Farmtiva has an exclusive partnership agreement with the not-for-profit group, Imperial Valley Conservation Research Center (“IVCRC”), and together they anticipate planting the first California hemp crop within the next three weeks. This project will be a first in California for hemp legally grown under the Agricultural Act of 2014 § 7606 (“2014 Farm Bill”) in California. As an “established agricultural research institution,” under Food and Agricultural Code (FAC) Section 81000, the project is exempt from registration and may currently grow industrial hemp in California. https://www.farmtiva.com
--- Be Tru Organics for 100% ownership on December 1st 2017. Be Tru is a formulator, marketer, and seller of a proprietary line of hemp extract products. Their offerings, which include topicals, oral sprays and edibles, contain powerful blends of more than 75 organic botanical terpenes and sold under the company’s Be Tru Organics™, Canatru™, and Cebatru™ brands. On december 13th, Be Tru Organics commenced the process of distributing product to Erewhon Natural Foods, a premier supermarket chain in California. https://betruwellness.com
--- C3 Global Biosciences for 100% ownership on December 8th 2017. C3GBS’s strategy involves using science and technology-based innovation to deliver better patient outcomes in areas of healthcare with the utmost need. With C3 Global Biosciences, Isodiol seeks to develop and advance proprietary, pharmaceutical-grade CBD Bioactive products that can produce positive real-world outcomes for patients and healthcare providers. C3GBS is an expert in conducting research, turning insights into tangible products, and incorporating those products into treatment programs. https://c3globalbiosciences.com
--- Bradley’s Bioscience Inc. for 100% ownership on November 22 2017. A leading manufacturer, and distributor of hemp oil and nicotine e-liquids. The acquisition of Bradley’s Bioscience, a market poised to be a $61.4 billion-dollar industry by 2025. Bradley’s Bioscience manufactures more than 500+ nicotine products across several brands; all of which are compliant with current FDA regulations and approved for sale in both the United States and internationally. https://bradleysbrand.com
--- Canadian National Pharma Group Inc. for 100% ownership on February 15th 2018. A pharmaceutical manufacturing company which is currently in the final stages of receiving its Licensed Dealer (“LD”) status under the provisions of the Canadian Controlled Drugs and Substances Act, in order to commence production of cannabis and hemp extracts or isolate. The agreement, which entails complete exclusivity to Isodiol for use of the license and facility, includes an option which provides Isodiol with rights of first refusal in future offerings, and to expand its ownership in CN Pharma to an overall controlling interest. CN Pharma has completed the build of a Health Canada compliant facility according to the highest standards for Health Canada’s final inspection, with more than 9,750 sq.ft of usable space, located in the city of Abbotsford, BC. https://canadiannationalpharmagroup.com
--- Pot-O-Coffee for 100% ownership on June 12 2017. A cannabis-based beverage company including the predominant brands Pot-O-Coffee, Pot-O-Tea, and Pot-O-Coco. This line of cannabis-infused single-serve coffee, tea and cocoa drinks aligns perfectly with the ever-expanding product offerings of the Company and positions it well within the explosive cannabis beverage market. On July 20th 2017, Isodiol has signed a licensing agreement with Canopy Growth Corporation (“Canopy”) (TSX:WEED). Canopy Growth Corporation will have the right to manufacture and distribute the Company’s “Pot-O-Coffee“ and “Pot-O-Tea” branded marijuana infused single serve K-Cup products in Canada and certain other markets internationally as federal regulations allow. Licensed products include caffeinated and de-caffinated product lines as well as Isodiol’s single serve “Pot-O-Coco”. In addition to the Canadian rights, Canopy Growth shall have the right of first refusal to sell the “Pot-O” brand products in any territory outside of the US, Mexico and Puerto Rico. On November 1st 2017, Isodiol has entered an agreement with Nutritional High (EAT:CNX), to distribute the Company’s Pot-O-Coffee, Pot-O-Tea, and Pot-O-Coco product lines. On April 5th 2018, Isodiol announced the product placement of Pot-O-Coffee and Pot-O-Tea in select Winn-Dixie stores throughout the East Coast. https://www.potocoffee.coffee
Isodiol appointed Dr. Ronald Aung-Din as a Medical, Science and Development Advisor to the Company. Dr. Aung-Din, a board-certified neurologist with more than 25 years of practice in general neurology and neuro-psychiatry, joins Isodiol after pioneering significant scientific advancements in the medical community. During his tenure, Dr. Aung-Din participated in more than 60 pharmaceutical-sponsored studies that proved to be instrumental in the development of numerous drugs for utilization and treatment of degenerative and neurological conditions. https://www.afginpharma.com/
Isodiol's websites and social media:
https://isodiol.com
https://iso-sport.com
https://www.instagram.com/isodiol
https://www.facebook.com/isodiol
https://bradleysbrand.com
https://www.kurevapes.com
https://kathyireland.com/healthandwellness
https://betruwellness.com
https://c3globalbiosciences.com
https://cbdxtreme.com
https://www.potocoffee.coffee
https://www.farmtiva.com
https://canadiannationalpharmagroup.com